Abbisko Cayman (HKG:2256) said Wednesday that its treatment, lavengratinib, has been granted "orphan designation" in Europe to treat achondroplasia, a genetic disorder that causes disproportionate dwarfism, according to a same-day bourse filing.
The company said lavengratinib is currently undergoing phase II trials in children aged 3-12 years with achondroplasia.
Shares of the company were up over 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.